Advertisement

New Drug Approved for Orthostatic Hypotension — Physician’s First Watch

Medical News |
February 20, 2014

New Drug Approved for Orthostatic Hypotension

By Kristin J. Kelley

Droxidopa capsules (marketed as Northera) have been granted accelerated approval to treat symptoms of neurogenic orthostatic hypotension associated with Parkinson disease, multiple-system atrophy, and pure autonomic failure, the FDA announced on Tuesday.

Approval was based on two clinical trials in which patients who took droxidopa for 2 weeks experienced decreased symptoms (e.g., dizziness, lightheadedness, feeling faint) compared with those on placebo. The most common side effects included headache, dizziness, and nausea.

The drug will carry a boxed warning about the increased risk for hypertension in the supine position; patients must be reminded to sleep with their heads and upper bodies elevated. Additionally, supine blood pressure should be monitored prior to and during treatment.

In January, an FDA advisory panel voted to grant approval for droxidopa, calling the decision "complex" due to questions about the drug's efficacy.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement